COMMUNIQUÉS West-GlobeNewswire

Polaryx Therapeutics Welcomes New Members of the Board of Directors
05/02/2026
PARAMUS, NJ, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics , Inc. (Nasdaq: PLYX ) a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of novel, disease- [...]
Vistin Pharma ASA (VISTN): Invitation to Q4 2025 conference call
05/02/2026
Oslo, Norway, 5 February 2026 Vistin Pharma ASA will release its fourth quarter and preliminary 2025 results on Thursday 12th of February 2025. Vistin Pharma will host a conference call for all shareholders and [...]
EXACT Therapeutics: Exercise of Warrants by GE Medical Holding AB
05/02/2026
GE Medical Holding AB exercises all its Warrants in EXACT Therapeutics resulting in gross proceeds of NOK 33 million. Reference is made to the stock exchange announcement published on 27 January 2026 by EXACT [...]
Aicuris Presents Positive Phase 3 Data for Pritelivir in Immunocompromised Patients with Refractory Herpes Simplex Virus at TANDEM
05/02/2026
Pritelivir met its primary endpoint of superior lesion healing, achieving a 62.7% lesion healing rate compared to 34.0% with standard-of-care therapies (investigator’s choice), resulting in an adjusted treatment [...]
Aclarion Publishes 2026 Shareholder Letter from the Chairman
05/02/2026
Company anticipates no capital raises prior to expected value enhancing catalysts Cash runway into 2028 ATM terminated in early 2025 and ELOC expired December 31, 2025 BROOMFIELD, Colo., Feb. 05, 2026 (GLOBE NEWSWIRE [...]
Zelluna ASA: Invitation to Fourth Quarter 2025 Results Webcast Presentation
05/02/2026
Oslo, Norway, 5 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, invites to a webcast presentation [...]
Biocomposites gains MDR certification for STIMULAN® Rapid Cure and STIMULAN® Kit
05/02/2026
STIMULAN ® certified to be mixed with a combination of Gram-positive and Gram-negative antibiotics STIMULAN ® certified to resolve infection and reduce the need for secondary surgery STIMULAN ® is the only calcium [...]
Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®
05/02/2026
The study, which assessed the pharmacokinetics, safety, tolerability and immunogenicity of AVT80 compared to Entyvio ® in healthy adult participants, met all its primary endpoints REYKJAVIK, Iceland, Feb. 05, 2026 ( [...]
Fagron obtains regulatory clearance for the acquisition of Vepakum in Brazil and completes the acquisition of Magilab in Hungary
05/02/2026
Regulated information - inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 5 February 2026 Fagron obtains regulatory clearance for the acquisition of Vepakum in Brazil and completes the acquisition of [...]
Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®
05/02/2026
The study, which assessed the pharmacokinetics, safety, tolerability and immunogenicity of AVT80 compared to Entyvio® in healthy adult participants, met all its primary endpoints REYKJAVIK, ICELAND (February 5, 2026) – [...]
Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer
05/02/2026
BMC128 was developed by Biomica, Evogene’s subsidiary, and is currently completing Phase 1 clinical study, showing promising early clinical results REHOVOT, Israel and SHANGHAI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Evogene [...]
GN Annual Report 2025: Solid execution leading to market share gains, DKK 1.1 billion free cash flow, and a strong foundation for profitable growth in the years ahead
05/02/2026
2025 highlights GN delivered revenue of DKK 16.8 billion with organic revenue growth of -1% (excluding wind-down), The Hearing division took market share – for the 4 th consecutive year – leading to 5% organic revenue [...]
Eikon Therapeutics Announces Pricing of Upsized Initial Public Offering
05/02/2026
MILLBRAE, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing important, innovative medicines to address serious unmet [...]
TruFull CBD Gummies: Product Disclosure Information Updated as CBD Supplement Research Grows in 2026
05/02/2026
Examining hemp-derived CBD supplement disclosures, third-party testing verification, THC-free claims, ingredient transparency, refund policies, and what consumers evaluate when researching full-spectrum CBD gummies in [...]
Neura Cognitive Health Supplement: Ingredient Facts, Label Guide, and Consumer Information for 2026
05/02/2026
An informational overview examining ingredient-level research context, Supplement Facts interpretation, and evaluation factors consumers consider when researching cognitive health supplement options New York, NY, Feb. [...]
Monthly information on share capital and company voting rights
04/02/2026
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the [...]
XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems
05/02/2026
CALGARY, Alberta, Feb. 04, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing [...]
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
04/02/2026
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 04 févr. 2026 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 Date Nombre total d’actions composant le [...]
STERIS Announces Financial Results for Fiscal 2026 Third Quarter
04/02/2026
Total revenue from continuing operations increased 9%; constant currency organic revenue grew 8% As reported EPS from continuing operations increased to $1.96; adjusted EPS increased to $2.53 Fiscal 2026 outlook [...]

Pages